Source-grounded facts extracted from Inhibikase Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Inhibikase Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $16.4 million, or $0.10 per share, EPS $0.10 per share.
“Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.”
Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.
“Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.”
Inhibikase Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters (effective 2025-11-20).
“On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to an aggregate of 22,873,779 shares of Common Stock (the “Pre-Funded Warrants” and the Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”).”
David McIntyre was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..
“Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).”
Garth Lees-Rolfe resigned as Chief Financial Officer at Inhibikase Therapeutics, Inc..
“Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).”
Vincent Aurentz was appointed as Class I director at Inhibikase Therapeutics, Inc..
“The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.”
Chris Cabell was appointed as President and Head of Research and Development at Inhibikase Therapeutics, Inc..
“the Board appointed Chris Cabell as President and Head of Research and Development of the Company.”
Mark Iwicki was appointed as Chief Executive Officer at Inhibikase Therapeutics, Inc..
“Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).”
Milton H. Werner resigned as Chief Executive Officer at Inhibikase Therapeutics, Inc..
“Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).”
Inhibikase Therapeutics, Inc.: Stockholders approved amendments to the Certificate of Incorporation to increase authorized common shares from 100,000,000 to 500,000,000 and eliminate the supermajority vote requirement for amendments to Article IV Section 1 (effective 2025-01-03).
“A Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. (the “ Company ”) was held on January 3, 2025. As further described in Item 5.07 to this Current Report on Form 8-K, at the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Amendment ”) to increase the number of the Company’s authorized shares of common stock from 100,000,000 shares to 500,000,000 shares and eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof, as described in the Company’s definitive proxy statement filed on November 18, 2024 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The Certificate of Amendment was previously approved by the Company’s board of directors, subject to approval by the Company’s stockholders. On January 3, 2025, the Company filed the Certif”
Gisele Dion resigned as director at Inhibikase Therapeutics, Inc..
“Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.”
Paul Grint resigned as director at Inhibikase Therapeutics, Inc..
“Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.”
Roberto Bellini was elected as Independent Chairperson of the Board at Inhibikase Therapeutics, Inc..
“The Board has elected Mr. Bellini as independent Chairperson of the Board.”
Arvind Kush was appointed as Class III director at Inhibikase Therapeutics, Inc..
“Arvind Kush to serve as a Class III director of the Board”
David Canner was appointed as Class II director at Inhibikase Therapeutics, Inc..
“Amit Munshi and David Canner to serve as Class II directors of the Board”
Amit Munshi was appointed as Class II director at Inhibikase Therapeutics, Inc..
“Amit Munshi and David Canner to serve as Class II directors of the Board”
Roberto Bellini was appointed as Class I director at Inhibikase Therapeutics, Inc..
“the Board appointed Roberto Bellini to serve as a Class I director of the Board”
Arvind Kush was appointed as Class III Director at Inhibikase Therapeutics, Inc..
“Arvind Kush to serve as a Class III director of the Board”
David Canner was appointed as Class II Director at Inhibikase Therapeutics, Inc..
“Amit Munshi and David Canner to serve as Class II directors of the Board”
Amit Munshi was appointed as Class II Director at Inhibikase Therapeutics, Inc..
“Amit Munshi and David Canner to serve as Class II directors of the Board”
Roberto Bellini was elected as Chairperson of the Board at Inhibikase Therapeutics, Inc..
“It is expected that the Board will elect Mr. Bellini as Chairperson of the Board”
Roberto Bellini was appointed as Class I Director at Inhibikase Therapeutics, Inc..
“the Board will appoint Roberto Bellini to serve as a Class I director of the Board”
Inhibikase Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $5,659,255 (effective 2024-02-01).
“On February 1, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with H.C. Wainwright & Co., LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $0.001 per share, in an aggregate offering price of up to $5,659,255 (the “ Shares ”) through the Agent.”
Garth Lees-Rolfe was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..
“The Board will appoint Garth Lees-Rolfe to serve as Chief Financial Officer of the Company upon Mr. Frattaroli’s retirement and until the earliest of his removal, termination, or resignation from such office.”
Joseph Frattaroli departed as Chief Financial Officer at Inhibikase Therapeutics, Inc..
“Joseph Frattaroli provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024.”
Inhibikase Therapeutics, Inc.: 1-for-6 reverse stock split via charter amendment (effective 2023-06-30).
“On June 28, 2023, Inhibikase Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect a 1-for-6 reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), on June 30, 2023.”
Inhibikase Therapeutics, Inc. shareholders rejected To approve an amendment to Article XII of the Company’s Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof at the 2023-06-23 meeting.
“Proposal Five : To approve an amendment to Article XII of the Company’s Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof. Total Votes For 15,474,907 Against 1,373,915 Abstain 180,767 Broker Non-Votes 6,084,269”
Inhibikase Therapeutics, Inc. shareholders approved To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the common stock of the Company within a range of 1-for-5 to 1-for-20, if needed to meet the minimum bid requirement under The Nasdaq at the 2023-06-23 meeting.
“Proposal Four : To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the common stock of the Company within a range of 1-for-5 to 1-for-20, if needed to meet the minimum bid requirement under The Nasdaq Capital Market listing rules with the exact ratio, if any, to be determined by the board of directors. Total Votes For 21,949,971 Against 1,156,412 Abstain 7,473 Broker Non-Votes 0”
Inhibikase Therapeutics, Inc. shareholders approved To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-23 meeting.
“Proposal Three : To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Total Votes For 22,817,751 Against 36,084 Abstain 260,023 Broker Non-Votes 0”
Inhibikase Therapeutics, Inc. shareholders rejected To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares at the 2023-06-23 meeting.
“Proposal Two : To grant discretionary authority to the board of directors to amend the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares. Total Votes For 20,642,707 Against 2,190,425 Abstain 280,725 Broker Non-Votes 0”
Inhibikase Therapeutics, Inc. shareholders approved Election of Dennis Berman and Gisele Dion as Class III directors at the 2023-06-23 meeting.
“Proposal One : To elect two directors to the board of directors of the Company to serve as Class III directors, to serve until the Company’s 2026 annual meeting of stockholders, or until in each case their respective successor is duly elected and qualified. The nominees for election were Dennis Berman and Gisele Dion. The following nominees were elected by the votes indicated to serve as Class III directors, to serve until the Company’s 2026 annual meeting of stockholders, or until in each case their respective successor is duly elected and qualified: Name Total Votes for Director Total Votes Withheld from Director Total Broker Non-Votes Dennis Berman 16,347,928 681,661 6,084,269 Gisele Dion 16,729,483 300,106 6,084,269”
Inhibikase Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
“H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the Offerings. The Company entered into an engagement letter (“Engagement Letter”) with Wainwright for potential financings.”
Inhibikase Therapeutics, Inc. entered into PIPE Purchase Agreement with the same institutional investor (effective 2023-01-25).
“The Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) in connection with a concurrent private placement (the “PIPE Private Placement”) with the same institutional investor (the “PIPE Purchaser” and, together with the Registered Direct Purchaser, the “Purchaser”).”
Inhibikase Therapeutics, Inc. entered into Registered Direct Purchase Agreement with an institutional investor (effective 2023-01-25).
“On January 25, 2023, Inhibikase Therapeutics, Inc. (“Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) in connection with a registered direct offering (the “Registered Direct Offering”) and concurrent private placement with an institutional investor (the “Registered Direct Purchaser”).”
Inhibikase Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“January 24, 2023, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notice from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for the market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Minimum Bid Price Requirement, and (ii) the Company”
Inhibikase Therapeutics, Inc. reported nine months ended September 30, 2022 results: net income $13.78 million, EPS $0.55 per share.
“Net loss for the nine months ended September 30, 2022, was $13.78 million or $0.55 per share”
Inhibikase Therapeutics, Inc. reported three months ended September 30, 2022 results: net income $4.49 million, EPS $0.18 per share.
“Net loss for the three months ended September 30, 2022 was $4.49 million, or $0.18 per share”
Gisele Dion was appointed as Director at Inhibikase Therapeutics, Inc..
“Following Ms. O’Farrell’s resignation, on September 1, 2022, the Board appointed Gisele Dion to serve as a Class III member of the Board.”
Elizabeth O’Farrell retired as Director at Inhibikase Therapeutics, Inc..
“On September 1, 2022, Elizabeth O’Farrell provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of her intention to retire from the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.